199 related articles for article (PubMed ID: 23232447)
1. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.
Dings RP; Kumar N; Miller MC; Loren M; Rangwala H; Hoye TR; Mayo KH
J Pharmacol Exp Ther; 2013 Mar; 344(3):589-99. PubMed ID: 23232447
[TBL] [Abstract][Full Text] [Related]
2. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity.
Mayo KH; Dings RP; Flader C; Nesmelova I; Hargittai B; van der Schaft DW; van Eijk LI; Walek D; Haseman J; Hoye TR; Griffioen AW
J Biol Chem; 2003 Nov; 278(46):45746-52. PubMed ID: 12947097
[TBL] [Abstract][Full Text] [Related]
3. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.
Dings RP; Miller MC; Nesmelova I; Astorgues-Xerri L; Kumar N; Serova M; Chen X; Raymond E; Hoye TR; Mayo KH
J Med Chem; 2012 Jun; 55(11):5121-9. PubMed ID: 22575017
[TBL] [Abstract][Full Text] [Related]
4. The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface.
Miller MC; Nesmelova IV; Platt D; Klyosov A; Mayo KH
Biochem J; 2009 Jun; 421(2):211-21. PubMed ID: 19432560
[TBL] [Abstract][Full Text] [Related]
5. NMR-based insight into galectin-3 binding to endothelial cell adhesion molecule CD146: Evidence for noncanonical interactions with the lectin's CRD β-sandwich F-face.
Zhang Z; Miller MC; Xu X; Song C; Zhang F; Zheng Y; Zhou Y; Tai G; Mayo KH
Glycobiology; 2019 Jul; 29(8):608-618. PubMed ID: 31094416
[TBL] [Abstract][Full Text] [Related]
6. Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity.
Nesmelova IV; Ermakova E; Daragan VA; Pang M; Menéndez M; Lagartera L; Solís D; Baum LG; Mayo KH
J Mol Biol; 2010 Apr; 397(5):1209-30. PubMed ID: 20184898
[TBL] [Abstract][Full Text] [Related]
7. Targeting the CRD F-face of Human Galectin-3 and Allosterically Modulating Glycan Binding by Angiostatic PTX008 and a Structurally Optimized Derivative.
Miller MC; Zheng Y; Suylen D; Ippel H; Cañada FJ; Berbís MA; Jiménez-Barbero J; Tai G; Gabius HJ; Mayo KH
ChemMedChem; 2021 Feb; 16(4):713-723. PubMed ID: 33156953
[TBL] [Abstract][Full Text] [Related]
8. The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain.
Miller MC; Klyosov A; Mayo KH
Glycobiology; 2009 Sep; 19(9):1034-45. PubMed ID: 19541770
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene.
Dings RP; Van Laar ES; Loren M; Webber J; Zhang Y; Waters SJ; Macdonald JR; Mayo KH
Bioconjug Chem; 2010 Jan; 21(1):20-7. PubMed ID: 20020769
[TBL] [Abstract][Full Text] [Related]
10. Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.
Miller MC; Ippel H; Suylen D; Klyosov AA; Traber PG; Hackeng T; Mayo KH
Glycobiology; 2016 Jan; 26(1):88-99. PubMed ID: 26646771
[TBL] [Abstract][Full Text] [Related]
11. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy.
Thijssen VL; Postel R; Brandwijk RJ; Dings RP; Nesmelova I; Satijn S; Verhofstad N; Nakabeppu Y; Baum LG; Bakkers J; Mayo KH; Poirier F; Griffioen AW
Proc Natl Acad Sci U S A; 2006 Oct; 103(43):15975-80. PubMed ID: 17043243
[TBL] [Abstract][Full Text] [Related]
12. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.
Ito K; Scott SA; Cutler S; Dong LF; Neuzil J; Blanchard H; Ralph SJ
Angiogenesis; 2011 Sep; 14(3):293-307. PubMed ID: 21523436
[TBL] [Abstract][Full Text] [Related]
13. Galectin-1 in melanoma biology and related neo-angiogenesis processes.
Mathieu V; de Lassalle EM; Toelen J; Mohr T; Bellahcène A; Van Goietsenoven G; Verschuere T; Bouzin C; Debyser Z; De Vleeschouwer S; Van Gool S; Poirier F; Castronovo V; Kiss R; Feron O
J Invest Dermatol; 2012 Sep; 132(9):2245-54. PubMed ID: 22622427
[TBL] [Abstract][Full Text] [Related]
14. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
15. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.
Kuo P; Bratman SV; Shultz DB; von Eyben R; Chan C; Wang Z; Say C; Gupta A; Loo BW; Giaccia AJ; Koong AC; Diehn M; Le QT
Clin Cancer Res; 2014 Nov; 20(21):5558-69. PubMed ID: 25189484
[TBL] [Abstract][Full Text] [Related]
16. Galectin-1-asialofetuin interaction is inhibited by peptides containing the tyr-xxx-tyr motif acting on the glycoprotein.
Wéber E; Hetényi A; Váczi B; Szolnoki E; Fajka-Boja R; Tubak V; Monostori E; Martinek TA
Chembiochem; 2010 Jan; 11(2):228-34. PubMed ID: 19938027
[TBL] [Abstract][Full Text] [Related]
17. Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.
Storti P; Marchica V; Airoldi I; Donofrio G; Fiorini E; Ferri V; Guasco D; Todoerti K; Silbermann R; Anderson JL; Zhao W; Agnelli L; Bolzoni M; Martella E; Mancini C; Campanini N; Noonan DM; Petronini PG; Neri A; Aversa F; Roodman GD; Giuliani N
Leukemia; 2016 Dec; 30(12):2351-2363. PubMed ID: 27311934
[TBL] [Abstract][Full Text] [Related]
18. Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas.
Rodríguez-Remírez M; Del Puerto-Nevado L; Fernández-Aceñero MJ; Cruz-Ramos M; García-García L; Solanes S; Molina-Roldán E; García-Foncillas J; Cebrián A
Neuroendocrinology; 2021; 111(1-2):146-157. PubMed ID: 31991407
[TBL] [Abstract][Full Text] [Related]
19. Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-κB signaling pathways.
Ma K; Wang C; Geng Q; Fan Y; Ning J; Yang H; Dong X; Dong D; Guo Y; Wei X; Li E; Wu Y
Oncol Rep; 2016 Jun; 35(6):3505-13. PubMed ID: 27035232
[TBL] [Abstract][Full Text] [Related]
20. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins.
Salomonsson E; Thijssen VL; Griffioen AW; Nilsson UJ; Leffler H
J Biol Chem; 2011 Apr; 286(16):13801-4. PubMed ID: 21372130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
